At least the ones Buster Olney has spoken to. He reports that he has spoken with dozens and dozens of ballplayers off the record in the past week, and that as many as 80-90% of them are upset at the Braun decision. They don’t like that he challenged procedure as opposed to substance, and they think it’s bad for the testing program overall, which they sincerely want to work.
I understand that. And I think it’s a good thing for drug testing in baseball overall that there are people who are upset at it. Like I said yesterday, systems are improved over time when blips and inefficiencies occur. The Braun decision may seem unjust on some level, but its lasting legacy will not be about what it means for Braun, it will be about how, when faced with a problem in the system, the league and the union can work together to address it. Which I am certain they will here, either by clarifying the collection procedures to their people in the field or by changing the Joint Drug Agreement to conform to the practices those in the field have employed and to apply them going forward.
All of that said, complaints that the Braun decision somehow puts testing at risk is silly. Braun walking on this charge is no more of a threat to the drug testing system than a guy getting off on a burglary charge because the cops didn’t get a proper search warrant is a threat to the criminal justice system. You may hate the result, but the remedy is easy: get it right next time or change the rules to make what happened in that instance acceptable. It is not something that puts the entire regime in peril.
Finally, I’ll observe that these complaints all seem a little self-righteous to me. No one who ever wins on a procedural argument themselves ever seems to have a problem with it. And I suspect that the 80-90% of the players Olney spoke with here were under the gun themselves, they would not hesitate to make the same arguments Braun did if they or their legal advisors thought to do so.
Free agent right-hander Tim Lincecum isn’t ready to hang up his cleats just yet. At least, that’s the word from Lincecum’s agent, Rick Thurman, who says the 32-year-old is still “throwing and getting ready for the season” (via Andrew Baggarly of the San Jose Mercury News).
Lincecum may not be ready to enter retirement, but another quote from Thurman suggests that he’ll be picky about where he pitches next. He doesn’t appear open to pitching overseas, and despite not having a contract for 2017 (or even any serious suitors), the right-hander is set on pitching in the big leagues this year. Whether or not he’s willing to take a bullpen role to do so remains to be seen.
While Baggarly predicts some interest in the veteran righty, there’s not much in Lincecum’s recent history to inspire faith in him as a starter, or even a reliever. He picked up a one-year, $2.5 million contract with the Angels following his hip surgery in 2015, and went 2-6 in 2016 with a 9.16 ERA, 5.4 BB/9 and 7.5 SO/9 over 38 1/3 innings. At this point, a minor league contract seems like the surest path back to major league success, though he’s unlikely to find an open spot on the Giants’ or Angels’ rosters anytime soon.
Free agent right-hander Jeff Manship has reportedly signed with the NC Dinos of the Korea Baseball Organization, according to FanRag Sports’ Jon Heyman. The righty was non-tendered by the Indians in December.
Manship, 32, completed his second season with Cleveland in 2016. He delivered a 3.12 ERA, 4.6 BB/9 and 7.5 SO/9 rate over 43 1/3 innings, a slight decline after posting an 0.92 ERA with the club the year before. During eight years in the major leagues, Manship carries a 4.82 career ERA, 3.6 BB/9 and 6.4 SO/9 in multiple stints with the Twins, Rockies, Phillies and Indians.
The right-hander will be joined by fellow MLB transplants Eric Hacker and Xavier Scruggs, each of whom took one-year deals with the Dinos last month. Steve Adams of MLB Trade Rumors notes that each KBO team is allowed up to three foreign players, so Manship will round out the trio when he joins the roster. Any salary terms have yet to be disclosed.